European Archives - Page 429 of 1207 - European Medical Journal

Sparking Discussions to Unravel Epilepsy

This podcast discusses the current field of epilepsy, raising awareness for aetiologies of this condition, and diagnostic and surgical journeys for patients.

Can Artificial Intelligence Predict Post-Nephrectomy Glomerular Filtration Rate?

Researchers have recently demonstrated that a fully automated AI approach can predict post-nephrectomy glomerular filtration rate with a level of accuracy comparable to validated clinical prediction models.

Bone Disorder Transformed Into Amyloidoma

Amyloidosis results from a misconfiguration of normal protein into β-plated linear sheets, leading to the formation and deposition of…

ECLS with Xenios console

Get to know Fresenius Medical Care’s ECMO offering – a dedicated technology combining both, heart and lung support in one single platform…

Latest Developments in Cardiac Surgery

Michael Reardon joins Jonathan to discuss the impact of transcatheter aortic valve implantation, and the treatment of cardiac tumours.

Artificial Intelligence Chatbot Outperforms Clinicians in Diagnosis Probability

According to a recent study, artificial intelligence chatbots outperformed human clinicians in probabilistic reasoning when estimating the probability of a diagnosis following a negative test result.

Working Together to Tackle Cancer

Find out how Daiichi Sankyo scientists are uncovering new ways to address needs in cancer.

Does Earlier Age of Menarche Increase Diabetes Risk in Females?

New research has indicated that early menarche could be linked to an increased risk of developing Type 2 diabetes, and for those who do, the risk of having a stroke before 65 years of age is also increased.

Low Inflammatory Index Diets Could Reduce Type 2 Diabetes Risk

According to research, low-inflammatory diets could influence the progression from prediabetes to Type 2 diabetes. Read for more details.

Patients with Myeloma Have Poorer Outcomes in Real-World Setting

Researchers found that real-world outcomes for individuals who received the standard treatment regimens for multiple myeloma were significantly poorer than outcomes reported in clinical trials.